ReviewMolecules (Basel, Switzerland)2026
Porphyrin-Based Compounds in Medicine: From Photodynamic Therapy to Theranostics.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porphyrins and their derivatives represent one of the most adaptable classes of compounds in contemporary biomedical research, bridging the crucial gap between diagnostic imaging and therapeutic intervention. This comprehensive review examines the evolution of porphyrin-based compounds and their therapeutic applications, from their fundamental role in photodynamic therapy to their status as sophisticated theranostic platforms. The unique photophysical properties of porphyrins, which are characterized by intense Soret band absorption, tunable fluorescence emission, and the generation of reactive oxygen species upon light activation, underpin their dual functionality as both imaging and therapeutic agents. The structural basis of porphyrin photochemistry, their progression through the first, second, and third generation of photosensitizers, and the transformative impact of nanotechnology, especially in overcoming intrinsic limitations such as poor aqueous solubility, aggregation-caused quenching, as well as limited tumor specificity, are discussed. Attention is devoted to emerging nanoplatforms such as porphyrin-based metal-organic frameworks (MOFs), covalent-organic frameworks (COFs), and electrospun nanofibers, which enable multimodal imaging, synergistic therapies, and controlled drug delivery. The challenges that impede clinical translation, including phototoxicity, tissue penetration limitations, and biosafety concerns, are critically examined, along with promising strategies for their resolution. By integrating porphyrin-based theranostic capabilities within single molecular platforms, these systems are ready to advance personalized cancer medicine while enabling real-time treatment monitoring and precision-guided interventions, which could substantially improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.